PBI 4050

Drug Profile

PBI 4050

Alternative Names: PBI-4050

Latest Information Update: 26 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ProMetic Life Sciences
  • Class Anti-inflammatories; Antifibrotics; Antihyperglycaemics; Skin disorder therapies; Small molecules
  • Mechanism of Action Autophagy stimulants; Cell differentiation modulators; Colony stimulating factor stimulants; Cytokine modulators; Erythropoiesis stimulants; Extracellular matrix protein inhibitors; Immunomodulators; Inflammation mediator inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Inborn genetic disorders; Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cystic fibrosis; Diabetic nephropathies; Idiopathic pulmonary fibrosis; Inborn genetic disorders; Metabolic syndrome; Scleroderma; Type 2 diabetes mellitus
  • Preclinical Acute lung injury; Pulmonary arterial hypertension; Renal fibrosis
  • No development reported Anaemia; Haematological disorders; Neutropenia

Most Recent Events

  • 25 Oct 2017 PBI 4050 receives Fast track status from the US FDA for Idiopathic pulmonary fibrosis
  • 25 Sep 2017 US FDA approves IND application for PBI 4050 in Idiopathic pulmonary fibrosis for phase II/III study
  • 19 Sep 2017 Prometic Life Sciences announces intention to conduct meetings to determine the clinical-regulatory pathway with US FDA and EMA for Inborn genetic disorders (Alstrom syndrome) in 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top